7651-99-2
Chemical Structure
Ethylenediaminetetra(methylenephosphonic acid) sodium
Synonym(s): EDTMP sodium
- CAS No.: 7651-99-2
- Formula:C6H15N2Na5O12P4
- Molecular Weight:546.03
IUPAC Name: sodium (((2-(bis((hydroxyoxidophosphoryl)methyl)amino)ethyl)((hydroxyoxidophosphoryl)methyl)amino)methyl)phosphonate
InChIKey: QPTMDBQLCWRDCK-UHFFFAOYSA-I
SMILES: O=P(CN(CP(O)(O[Na])=O)CCN(CP(O)(O[Na])=O)CP(O)(O[Na])=O)(O[Na])O[Na]
Biological Activity: Ethylenediaminetetramethylenephosphonic acid (EDTMP) sodium is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid sodium is used to study palliative therapy for pain associated with multiple bone metastatic cancers[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ethylenediaminetetra(methylenephosphonic acid) sodium | Ethylenediaminetetramethylenephosphonic acid (EDTMP) sodium is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid sodium is used to study palliative therapy for pain associated with multiple bone metastatic cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Askari E, et al. 177Lu-EDTMP for Metastatic Bone Pain Palliation: A Systematic Review and Meta-Analysis. Cancer Biother Radiopharm. 2021;36(5):383-390. [Content Brief]
- [2]. Maini CL, et al. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31 Suppl 1:S171-S178. [Content Brief]
-
[3]. Holmes RA. [153Sm] EDTMP: a potential therapy for bone cancer pain. InSeminars in nuclear medicine 1992 Jan 1 (Vol. 22, No. 1, pp. 41-45). WB Saunders.
